[go: up one dir, main page]

MX2014009751A - Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. - Google Patents

Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.

Info

Publication number
MX2014009751A
MX2014009751A MX2014009751A MX2014009751A MX2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A
Authority
MX
Mexico
Prior art keywords
antibodies
integrin
avvb6
same
treat cancer
Prior art date
Application number
MX2014009751A
Other languages
English (en)
Other versions
MX360141B (es
Inventor
Maureen Ryan
Django Sussman
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2014009751A publication Critical patent/MX2014009751A/es
Publication of MX360141B publication Critical patent/MX360141B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención proporciona anticuerpos que se unen específicamente a integrina avß6. Los anticuerpos son útiles para el tratamiento y el diagnóstico de diversos tipos de cáncer, así como la detección de avß6.
MX2014009751A 2012-02-17 2013-02-14 Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. MX360141B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600499P 2012-02-17 2012-02-17
US201261602511P 2012-02-23 2012-02-23
PCT/US2013/026087 WO2013123152A2 (en) 2012-02-17 2013-02-14 ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Publications (2)

Publication Number Publication Date
MX2014009751A true MX2014009751A (es) 2015-02-24
MX360141B MX360141B (es) 2018-10-24

Family

ID=48984888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009751A MX360141B (es) 2012-02-17 2013-02-14 Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.

Country Status (13)

Country Link
US (5) US9493566B2 (es)
EP (1) EP2814509B1 (es)
JP (1) JP6273214B2 (es)
KR (1) KR102084806B1 (es)
CN (2) CN105017420B (es)
AU (1) AU2013221585B2 (es)
BR (1) BR112014019861A2 (es)
CA (1) CA2862319C (es)
EA (1) EA031069B1 (es)
IL (1) IL233742B (es)
MX (1) MX360141B (es)
SG (1) SG11201404354UA (es)
WO (1) WO2013123152A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2789684T3 (en) 2008-05-23 2017-02-20 Siwa Corp Methods and compositions for facilitating regeneration
CN106232625B (zh) * 2013-10-01 2020-04-24 免疫医疗有限公司 治疗和诊断过表达α-V-β-6的癌症的方法
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
MX385823B (es) 2014-02-17 2025-03-18 Seagen Inc Conjugados de anticuerpo-farmaco hidrofilicos.
WO2015164627A1 (en) * 2014-04-23 2015-10-29 Discovery Genomics, Inc. Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP4067386A1 (en) 2016-02-19 2022-10-05 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3496747A4 (en) 2016-08-09 2020-04-15 Seattle Genetics, Inc. Drug conjugates with self-stabilizing linkers having improved physiochemical properties
KR20230144096A (ko) 2016-10-18 2023-10-13 씨젠 인크. 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
EP3535397B1 (en) * 2016-11-01 2022-01-05 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
WO2018175994A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
JP7425606B2 (ja) 2017-04-27 2024-01-31 シージェン インコーポレイテッド 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
US11597701B2 (en) * 2017-11-01 2023-03-07 Arrowhead Pharmaceuticals, Inc. Integrin ligands and uses thereof
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
AU2019225845B2 (en) 2018-02-20 2024-06-20 Seagen Inc. Hydrophobic Auristatin F compounds and conjugates thereof
US20240199735A1 (en) * 2019-07-22 2024-06-20 The Methodist Hospital Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer
JP7551750B2 (ja) * 2019-12-05 2024-09-17 シージェン インコーポレイテッド 抗αｖβ６抗体及び抗体薬物コンジュゲート
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
US20230173093A1 (en) 2020-04-10 2023-06-08 Seagen Inc. Charge variant linkers
WO2022198231A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022216920A1 (en) 2021-04-08 2022-10-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
TW202304514A (zh) 2021-04-20 2023-02-01 美商思進公司 抗體依賴性細胞毒性之調節
CN117580593A (zh) 2021-05-28 2024-02-20 思进公司 蒽环霉素抗体结合物
KR20250004952A (ko) 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer
WO2024263932A2 (en) 2023-06-23 2024-12-26 Mythic Therapeutics, Inc. Itgb6-binding proteins and uses thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
ATE410179T1 (de) 1997-08-08 2008-10-15 Univ California Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern
US7318923B2 (en) 2001-04-30 2008-01-15 Eli Lilly And Company Humanized anti-βantibodies
UA90242C2 (ru) * 2002-03-13 2010-04-26 Байоджен Айдек Ма Инк. МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С αVβ6
NZ535425A (en) * 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
EP1492870A4 (en) 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
US7241598B2 (en) * 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
US20090285806A1 (en) * 2004-10-05 2009-11-19 Martin Sinacore Methods and compositions for improving recombinant protein production
KR101281501B1 (ko) * 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
JP2009505673A (ja) 2005-08-31 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー 第ｖｉｉ因子特異抗体及びその使用
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
JP5362563B2 (ja) 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
EP2087008A1 (en) 2006-10-19 2009-08-12 The Regents of the University of California TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6
CA2711557A1 (en) * 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
KR20100106590A (ko) * 2008-01-22 2010-10-01 바이오겐 아이덱 엠에이 인코포레이티드 Ｒｏｎ 항체 및 이들의 용도
JP5467997B2 (ja) 2008-03-27 2014-04-09 テルモ株式会社 生体吸収性材料およびそれを用いた生体内留置物
AU2009245724A1 (en) 2008-05-09 2009-11-12 Ablynx N.V. Amino acid sequences directed against integrins and uses thereof
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
CA2818548A1 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
WO2013148316A1 (en) 2012-03-29 2013-10-03 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications

Also Published As

Publication number Publication date
EA031069B1 (ru) 2018-11-30
US9493566B2 (en) 2016-11-15
CN105017420A (zh) 2015-11-04
EP2814509A4 (en) 2015-12-09
EA201491541A1 (ru) 2016-05-31
IL233742B (en) 2019-08-29
CA2862319A1 (en) 2013-08-22
KR20140127875A (ko) 2014-11-04
US20210340260A1 (en) 2021-11-04
KR102084806B1 (ko) 2020-03-04
CN105017420B (zh) 2019-05-28
WO2013123152A3 (en) 2014-11-13
JP2015509938A (ja) 2015-04-02
US20160009806A1 (en) 2016-01-14
EP2814509A2 (en) 2014-12-24
CN104220094A (zh) 2014-12-17
US20160376368A1 (en) 2016-12-29
BR112014019861A2 (pt) 2017-07-04
MX360141B (es) 2018-10-24
EP2814509B1 (en) 2018-05-16
CA2862319C (en) 2021-11-30
WO2013123152A2 (en) 2013-08-22
JP6273214B2 (ja) 2018-01-31
SG11201404354UA (en) 2014-10-30
US20230242648A1 (en) 2023-08-03
IL233742A0 (en) 2014-09-30
HK1211035A1 (en) 2016-05-13
AU2013221585B2 (en) 2017-03-30
AU2013221585A1 (en) 2014-08-14
US20200031938A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
TN2015000396A1 (en) Antibody drug conjugates
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
SG10201704992SA (en) Lsr antibodies, and uses thereof for treatment of cancer
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX337577B (es) Anticuerpos c-kit y usos de los mismos.
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
EA201400178A1 (ru) Лечение рака молочной железы
UA117663C2 (uk) Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
IN2014DN09717A (es)
MX353951B (es) Anticuerpos de anti-teofilina y metodos de uso.
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
IL232340A0 (en) lsr antibodies, and their uses for cancer treatment

Legal Events

Date Code Title Description
FG Grant or registration